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Abstract
Objective
To report cross-sectional clinical ﬁndings in a large cohort of patients aﬀected by type 1 spinal
muscular atrophy.
Methods
We included 122 patients, of age ranging between 3 months and 22 years, 1 month. More than
70% (85/122) were older than 2 years and 25% (31/122) older than 10 years. Patients were
classiﬁed according to the severity of phenotype and to the number of SMN2 copies.
Results
Patients with the more common and the most severe phenotype older than 2 years were, with
few exceptions, on noninvasive ventilation and, with increasing age, more often had trache-
ostomy or >16-hour ventilation and a gastrostomy inserted. In contrast, 25 of the 28 patients
with the mildest phenotype older than 2 years had no need for tracheostomy or other venti-
latory or nutritional support. In patients older than 2 years, the Children’s Hospital of Phila-
delphia Infant Test of Neuromuscular Disorders scores were generally lower compared to those
found in younger patients and showed distinct levels of functional abilities according to the
severity of the phenotype. Similar ﬁndings were also observed on the Hammersmith Infant
Neurological Examination.
Conclusions
Our ﬁndings conﬁrm that, after the age of 2 years, patients with type 1 spinal muscular atrophy
generally survive only if they have gastrostomy and tracheostomy or noninvasive ventilation
>16 hours and have low scores on the functional scales. More variability, however, can be
expected in those with the mildest phenotype, who achieve head control. These data provide
important baseline information at the time treatments are becoming available.
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Spinal muscular atrophy (SMA) is an autosomal recessive
disorder caused by mutations in the survival of motor neu-
ron 1 (SMN1) gene.1 Nusinersen, an antisense oligonucle-
otide designed to increase full-length SMN protein levels,
has recently been used in phase 22,3 and phase 3 sham-
controlled studies in infants with infantile-onset SMA
showing increased survival and some improvement on mo-
tor functional scales.4 Similar results have been observed in
a parallel phase 3 sham-controlled study in late-onset spinal
SMA.5 Based on these results, the drug has recently been
approved in several countries. While waiting for regulatory
approval, nusinersen was made available via an early access
program (EAP) to allow early access to all patients with type
1 SMA. In Italy, a national committee was created to identify
all the patients potentially eligible for the EAP and facilitate
the process.6 This allowed identiﬁcation of patients who
were not regularly followed in tertiary care centers and to
systematically collect information in a large cohort of
patients with type 1 SMAwhose age ranged from neonatal to
young adult.
Our aim was to report functional abilities and other clinical
ﬁndings at baseline, before treatment with nusinersen was
started, to provide a cross-sectional picture of a large cohort of
patients with type 1 SMA in Italy with a wide age range and to
retrospectively evaluate whether and how survival and func-
tional abilities were inﬂuenced by onset and severity of the
disease or diﬀerent modalities of intervention.
Methods
A nationwide search was performed to identify all patients
with type 1 SMA in Italy. The search started from the national
registries of SMA, but all the tertiary neuromuscular centers,
rehabilitation/counseling centers with known expertise in
SMA, and genetic laboratories were also consulted and in-
formed of the EAP. Details of this procedure have already
been reported.6
Inclusion criteria included a genetically conﬁrmed diagnosis
of SMA with a homozygous deletion of exon 7 or other
mutations in the SMN1 gene, and a clinically conﬁrmed
diagnosis of type 1 SMA (inability to achieve independent
sitting). One hundred ﬁfty-six patients with SMA1 were
identiﬁed. Two of them, with onset of clinical signs before 6
months, were excluded because they had achieved the
ability to sit unsupported. Another 3 died (ages between 1
and 5 months) before they could be seen at one of the
participating centers. Of the remaining 151, 99 agreed to be
part of the program while the other 52 did not reply or had
no interest in joining the EAP (age range 1 month to 13
years). Twenty-three additional patients were diagnosed
after the program started and were also included, thus
resulting in a ﬁnal cohort of 122 patients. None of these
patients were part of other clinical trials.
The patients were followed in 5 centers (2 in Rome, 1 in
Genova, 1 in Milan, and 1 in Messina) that had already been
involved in previous nusinersen trials.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the ethics committee in each
center. Written informed consent was obtained from all par-
ticipants (or guardians of participants) in the study.
A structured pro forma was used to collect current and ret-
rospective clinical data. This included age at onset, maximal
motor function achieved (e.g., head control), acquisition of
speech, and, when available, analysis of retrospective func-
tional data. This allowed the investigators at each site to
classify the patients according to the Dubowitz decimal clas-
siﬁcation7 that identiﬁes as 1.5 the infants with the phenotype
observed in the majority of type 1 SMA: inability to raise the
legs against gravity or maintain the head posture either in the
supine or prone position, but having, at diagnosis, no diﬃculty
with feeding and swallowing, no accumulation of pharyngeal
secretions, and no obvious distress. At the more severe end of
the spectrum, the infants had severe paralysis at birth and early
respiratory and bulbar diﬃculties and an overtly poor prog-
nosis for survival (type 1.1), while at the other end of the
spectrum, infants had some head control and less respiratory
compromise (type 1.9). This classiﬁcation partially overlaps
with a more recently proposed classiﬁcation in 3 subtypes8,9:
type 1A, presentation at birth with joint contractures and need
for respiratory support, or onset of motor and respiratory
involvement in the ﬁrst week; type 1B, symptom onset after
the neonatal period, usually before age 3 months, and head
control never achieved; and type 1C, onset after the neonatal
period, usually between 3 and 6 months, and head control
achieved. We applied both classiﬁcations in this analysis.
Need for ventilator or nutritional support and time when
these were initiated were also collected. SMN2 copy number,
if DNA samples were available, was also determined by the
commercial MLPA kit (SALSA MLPA probemix P021-A2
SMA; MRC-Holland, Amsterdam, the Netherlands) or by
quantitative PCR.10
Glossary
CHOP INTEND = Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; EAP = early access program;
HINE = Hammersmith Infant Neurological Examination; PEG = percutaneous endoscopic gastrostomy; SMA = spinal
muscular atrophy.
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Children’s Hospital of Philadelphia Infant Test
of Neuromuscular Disorders
The Children’s Hospital of Philadelphia Infant Test of Neu-
romuscular Disorders (CHOP INTEND) is speciﬁcally
designed to assess motor function in weak infants, and has
been validated in type 1 SMA.11,12 It includes 16 items with
a total score that can range from 0 to 64. The scale was
performed by clinical evaluators trained by the senior physical
therapist (R.d.S.) after training and reliability sessions.
Hammersmith Infant
Neurological Examination
The developmental section of the Hammersmith Infant Neu-
rological Examination (HINE)13 is a short assessment, easily
performed even in fragile, weak type 1 SMA. It includes 8
selected motor items that document developmental progress
(ﬁgure 1), allowing not only the opportunity to record whether
the various milestones have been achieved but also to quantify
intermediate steps leading to the full achievement of the
milestone. Each item provides the opportunity to score the level
of development on a 5-point scale with 0 as absence of the
activity. These milestones were designed according to the
gradient of normal maturation. The module was originally
designed as a part of a general neurologic examination and was
not speciﬁcally designed for patients with neuromuscular
weakness. Nevertheless, 7 of the 8 items reﬂect the maturation
of the milestone from absence of the response to the achieve-
ment of the milestone involving antigravity movements. The
only item that does not follow a similar maturation and is more
related to maturation of coordination in ﬁne motor abilities is
hand grasp and therefore was excluded from the analysis, as also
suggested in a recent clinical trial using the same assessment.4
Statistical analysis
Statistical analysis was performed with a dedicated software
program, IBM SPSS Statistics release 22 (IBM, Armonk, NY).
All data are presented as mean values and SD for continuous
variables. One-way analysis of variance with Bonferroni post
hoc test was used to compare continuous variables between
groups. The level of signiﬁcance was set at p = 0.05.
Results
One hundred twenty-two patients with type 1 SMA (66
female, 56 male) were included in the study. Their ages
ranged between 3 and 266 months (mean 73, SD 64.7). The
age at onset ranged between 0 and 8 months (mean 3.33, SD
1.9). Three of the 122 had 1 SMN2 copy, 75 had 2 copies, 25
had 3, and 2 had 4 copies. In 17 patients, a DNA sample was
not available, and SMN2 copy number was not determined.
Classification
Twelve patients were classiﬁed as type 1.1, 73 as 1.5, and 37 as
1.9. Fifteen were classiﬁed as type 1A, 73 as 1B, and 34 as 1C.
Table 1 shows the correlation between the 2 classiﬁcation
systems with 112 of the 122 patients (91.8%) having con-
cordance between the 2 systems.
SMA subtype and ventilatory support
Figure 1 shows details of the level of respiratory care in the
cohort according to the age when they were assessed and the
subtype.
All the patients classiﬁed as 1.1 who survived after the age of 6
months had tracheostomy or >16 hours of ventilation.
Of the patients classiﬁed as 1.5, none of those younger than 1
year had a tracheostomy or >16 hours of ventilation. The
Figure 1 Details of the level of respiratory care by age and
subtype
(A) Type 1A, (B) type 1B, and (C) type 1C. bipap = bilevel positive airway
pressure.
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number of tracheostomies progressively increased in the older
patients.
In the patients classiﬁed as 1.9, only 3 of the 37 (1 seen at
the age of 35 months, 1 at 12 years, and 1 at 13 years) had
a tracheostomy or >16 hours of ventilation.
SMA subtype and nutritional difficulties
Figure 2 shows details of the level of nutritional diﬃculties in
the cohort according to the age when they were assessed and
the subtype.
Of the patients classiﬁed as 1.1, with one exception, none
survived after the age of 6 months without gastrostomy. In the
patients classiﬁed as 1.5, 2 of the 4 assessed between 6 and 12
months of age had a percutaneous endoscopic gastrostomy
(PEG). The number of PEGs progressively increased in the
older patients. In the patients classiﬁed as 1.9, only one of the
patients younger than 24 months had a PEG tube inserted.
The number of PEGs progressively increased in the older
patients, but even after the age of 4 years, less than 50% of the
1.9 patients had a PEG tube inserted.
Speech
Thirty-four patients (28%) acquired comprehensible speech,
i.e., were able to produce at least short sentences that could be
understood by the examiner and not just by the carers. Thirty
were 1.9 patients (30/37 = 81% of the type 1.9 patients) and 4
were 1.5 (4/73 = 1.9% of the type 1.5 patients).
CHOP INTEND
The scores ranged between 0 and 52 (table 2). Patients with
type 1.1, with one exception, never had scores above 8 with
a mean score of 4.08 (SD 4.5); in patients with 1.5 SMA, the
mean score was 9.42 (SD 10.13) and in patients with 1.9 was
25.67 (SD 12.5). As expected, with increasing age, there was
a decrease in total scores in all the subgroups (ﬁgure 3).
There was a diﬀerence among patients with diﬀerent subtypes
of SMA according to the decimal classiﬁcation (p < 0.001).
Similarly, there was also a diﬀerence among patients with
diﬀerent subtypes of SMA according to the more recent
classiﬁcation (p < 0.001). The mean score in patients with 1A
SMA was 5.4 (SD 7.2); in patients with 1B SMA, the mean
score was 10 (SD 10.35) and in patients with 1C was 25.76
(SD 12.99). As expected, with increasing age, there was
a decrease in total scores in all the subgroups.
Figure 4 shows the distribution of scores according to age and
SMN2 copies, and that there are diﬀerences among patients
with diﬀerent SMN2 copy numbers (p < 0.001).
Hammersmith Infant
Neurological Examination
All patients with 1.1 phenotype and 94.5% of the 1.5 had
a total score of 0 (mean score 0.08, SD 0.36) (table 2), irre-
spective of their age. Scores of 1 or more were found in 74% of
the 1.9 patients (mean score 1.57, SD 1.36) with higher scores
in the younger group. There was a diﬀerence among patients
with diﬀerent subtypes of SMA, using both the decimal and
Table 1 Correlation between the 2 classification systems
on 112 of 122 patients (91.8%)
1.1 (n = 12) 1.5 (n = 73) 1.9 (n = 37)
1A (n = 15) 11 4 —
1B (n = 73) 1 68 4
1C (n = 34) — 1 33
Figure 2 Details of level nutritional difficulties by age and
subtype
(A) Type 1A, (B) type 1B, and (C) type 1C. PEG = percutaneous endoscopic
gastrostomy; SNG = nasogastric tube.
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the more recent classiﬁcation (p < 0.001). Similarly, there was
also a diﬀerence (p < 0.001) when patients were subdivided
according to the number of SMN2 copies.
Discussion
In the last few years, there has been an eﬀort to collect sys-
tematic prospective longitudinal studies in young infants with
type 1 SMA.9,14–17 These studies have been important to
provide natural history data for comparison to the results of
the completed and ongoing clinical trials including young
infants enrolled in the ﬁrst months of life.4,18–20 The EAP has
provided an opportunity to identify a wider group of type 1
patients, including older patients, and to assess their func-
tional status. The involvement of genetic and rehabilitation
centers, in addition to all the tertiary care centers, allowed us
to identify a much higher number of type 1 patients than those
registered in the Italian national registry for SMA. There were
152 type 1 patients identiﬁed, with an additional 21 newly
diagnosed patients obtained during the 9 months after the
program started. Because 122 of the 173 patients agreed to
Table 2 CHOP INTEND and HINE scores according to the 2 classification systems and SMN2 copy number
Decimal classification Recent classification (A, B, C) SMN2 copy number
1.1
(n = 12)
1.5
(n = 73)
1.9
(n = 37)
1A
(n = 15)
1B
(n = 73)
1C
(n = 34)
1 copy
(n = 3)
2 copies
(n = 75)
3 copies
(n = 25)
4 copies
(n = 2)
CHOP INTEND
Range 0–15 0–42 1–52 0–21 0–42 1–52 0–31 0–39 1–52 23–28
Mean 4.08 9.42 25.67 5.40 10.00 25.76 12.67 10.80 26.56 25.50
SD ±4.50 ±10.13 ±12.50 ±7.20 ±10.35 ±12.99 ±16.26 ±11.19 ±12.69 ±3.53
HINE
Range 0–0 0–2 0–5 0–0 0–2 0–5 0–3 0–3 0–5 0–0
Mean 0.08 1.57 0.14 1.59 1.00 0.28 1.44
SD ±0.36 ±1.36 ±0.48 ±1.39 ±1.73 ±0.69 ±1.56
Abbreviations: CHOP INTEND = Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE = Hammersmith Infant Neurological
Examination.
Figure 3 Distribution of raw scores on the CHOP INTEND by age and SMA 1 subtype
CHOP INTEND = Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; SMA = spinal muscular atrophy.
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assessment and to discuss possible enrollment in the EAP, we
were able to include more than 70% of the type 1 who could
be identiﬁed in Italy.
The patients who refused intervention or to share their data
were at the 2 extremes, either newly diagnosed for whom
parents decided to follow a palliative approach, or some of the
older patients with tracheostomy. For those patients, the
families expressed concern that the risks associated with
traveling and the time spent in hospital for the frequent
procedures could outtake the possible beneﬁts, because at that
time, there was no evidence of the eﬀect of nusinersen in
patients older than those enrolled in the clinical trials.
While we cannot describe this as a population-based study,
this is probably the closest attempt for a real-life prevalence
study that, during the EAP, will prospectively collect func-
tional data on a national level. The ﬁnal cohort included 122
patients who were all assessed at baseline, before starting
treatment. A number of patients were newly diagnosed or
within 24 months of age, but more than 70% (85/122) were
older than 2 years and 25% (31/122) were older than 10
years. We therefore included patients that are generally not
reported in natural history studies.
Our data showed a marked diﬀerence between patients with
the mildest phenotype compared to the others. As expected,
in the more common and in the most severe phenotype,
patients older than 2 years were, with few exceptions, on
noninvasive ventilation, and with increasing age, more often
had tracheostomy or >16 hours of ventilation. Similarly, more
than 80% of the 1.1 and 1.5 patients older than 2 years had
undergone gastrostomy, with increasing frequency with in-
creasing age.
These results conﬁrm previous observations that, after the age
of 2 years, survival is generally only possible in the presence of
tracheostomy/continuous ventilation and nutritional
support.21,22 However, there were patients who had no need
for tracheostomy or other ventilator or nutritional support
after the age of 2. With few exceptions, these were patients
with the mildest phenotype (1.9 or 1C). Because this was not
a prospective longitudinal study, we cannot establish how
these patients are representative of the whole cohort of 1.9, as
we do not have the numbers of those who did not survive. All
patients who survived after the age of 10 years without a tra-
cheostomy or >16 hours of ventilation had relatively later
onset, achieved head control, and had an overall milder dis-
ease course from onset. This was particularly true in 3 patients
with 1.9 phenotype in whom the onset of clinical signs oc-
curred soon after the age of 6 months. These patients had high
scores on the CHOP and HINE, achieved head control, and,
in 2 cases, also developed the ability to talk and had the best
motor and respiratory outcomes. Because they never achieved
the ability to sit unsupported, they were still strictly classiﬁed
as type 1 and resemble the cases previously described by
Dubowitz1 as borderline. This was not always related to
a higher number of SMN2 copies; while 2 of the 3 had 3
SMN2 copies, the other had 2 copies.
The CHOP INTEND scores in patients older than 2 years
were generally lower compared to those found in younger
Figure 4 Distribution of raw scores on the CHOP INTEND by age and SMN2 copy number
CHOP INTEND = Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders.
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patients. As reported in a recent article describing CHOP
INTEND scores in diﬀerent type 1 subtypes in the ﬁrst years
after birth,17 we found that the CHOP INTEND can identify
distinct levels of functional abilities in the 3 subgroups;
patients with the mildest phenotype have relatively high
scores compared to the others.
A similar trend was also observed on the HINE2 as patients
with themildest phenotypes were the only ones to have scores
>2. In contrast, the HINE did not diﬀerentiate between 1.1
and 1.5, as the great majority had a score of 0, in keeping with
our recent natural history data.16
Over the last few years, diﬀerent classiﬁcations of type 1 SMA
have become available and there are still some controversies
on some aspects of classiﬁcation, mainly related to the onset
of the diﬀerent subgroups. Using both the Dubowitz decimal
classiﬁcation23 and the more recently proposed classiﬁcation,8
we found that the concordance between type 1.1 and 1A, type
1.5 and 1B, and 1.9 and 1C was overall very good (111/121 =
91%). The concordance was higher in the 1.5/1B and 1.9/1C
subgroups (93% and 97%, respectively), while there was more
discordance in the severe end of the spectrum. Onset at birth
(n = 3) or within the ﬁrst 2 weeks (n = 12), found in our 15
patients with type 1A, was not always associated with themost
severe phenotype (1.1 in the decimal classiﬁcation), as 4 of the
15 (1/3 at birth and 3/12 in the ﬁrst 2 weeks) developed the
milder, most typical phenotype (1.5 in the decimal classiﬁ-
cation). These patients, even though they had a very early
onset of symptoms, had some distal movements and a less
compromised respiratory function with less marked appear-
ance of the involvement of the chest respiratory muscles, as
observed in the more common type 1.5 phenotype. These
ﬁndings suggest that caution should be used to classify severe
patients only on the basis of onset and that a clinical assess-
ment of severity of the motor and respiratory signs provides
additional prognostic information.
Although patients with 3 copies had, as a group, better ﬁnd-
ings than those with 2 copies, as already reported in previous
studies, this did not always hold true for individual cases. In
our cohort, 2 patients had 4 copies and they did not show
amilder phenotype. This information can be useful at the time
there is the suggestion to use newborn screening algorithms
focused on SMN2 copy number to identify patients with SMA
eligible for treatment.
Our data provide a snapshot of functional abilities in a wide
cohort of patients with type 1, subdivided according to sub-
types and SMN2 copy number, including patients older than
10 years who are generally not included in type 1 natural
history studies. Similar studies should be encouraged, because
natural history studies in untreated patients will soon no
longer be feasible as the prospectively collected natural history
will henceforth reﬂect the increasing number of patients
treated with nusinersen (Spinraza; Biogen, Cambridge, MA),
and it is hoped that, in the near future, other treatments as well.
Another study reported systematic data on ventilatory and
nutritional support in a large cohort of patients with type 1
SMA, but no detailed information on the subtypes or the
SMN2 copy number was available.22
Our ﬁndings conﬁrm that, after the age of 2 years, type 1
patients with early onset and those with the most common
phenotype (1.1/A and 1.5/B) who survive, generally have
tracheostomy and gastrostomy and have very low scores on
the CHOP INTEND. More variability can be found in those
with the mildest phenotype, who achieve head control. These
data provide important baseline information to establish the
possible eﬃcacy of nusinersen in a real-life setting, in a wider
population that will include patients who do not have the
inclusion criteria used in the clinical trials.2,4
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